Evidence map›Paper›PMID 41096701›Full record

ReviewInternational journal of molecular sciences2025

Molecular Mechanism Discovery of Acacetin Against Cancers: Insights from Network Pharmacology and Molecular Docking.

Jung Yoon Jang, Donghwan Kim, Eunok Im, Na Kyeong Lee, Nam Deuk Kim

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Phytochemical Diversity and Antioxidant Potential ofAntioxidants (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jung Yoon JangDepartment of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0003-2309-0996
Donghwan KimFunctional Food Materials Research Group, Korea Food Research Institute, Wanju-gun 55365, Jeollabuk-do, Republic of Korea.ORCID 0000-0002-0139-2494
Eunok ImDepartment of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0002-9949-8819
Na Kyeong LeeDepartment of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.
Nam Deuk KimDepartment of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.ORCID 0000-0001-9033-9865

Funding

Pusan National University This work was supported by a two-year research grant by Pusan National University
6 · The paper itself

Abstract

Acacetin, a naturally occurring flavonoid, has attracted increasing attention due to its broad anticancer potential. In vitro and in vivo studies using diverse tumor models have demonstrated that acacetin modulates oncogenic signaling, suppresses angiogenesis, and induces apoptosis and other regulated cell death pathways. With the rising demand for multi-target therapeutics, network pharmacology and molecular docking have emerged as powerful tools to unravel the complex molecular mechanisms of phytochemicals. Unlike previous reviews that have mainly focused on single pathways or limited cancer contexts, this review emphasizes novelty by integrating network pharmacology with molecular docking and explicitly linking these computational predictions to experimental validation, thereby identifying epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), and the serine/threonine kinase AKT (also known as protein kinase B (PKB) as central experimentally supported targets. This integrative framework maps acacetin's multi-target anticancer mechanisms and clarifies its translational opportunities for future therapeutic development.

Indexed as

Antineoplastic AgentsFlavonesMolecular Docking SimulationNeoplasmsNetwork PharmacologyAnimalsDrug DiscoveryErbB ReceptorsHumansProto-Oncogene Proteins c-aktSignal TransductionSTAT3 Transcription FactoracacetinAntineoplastic AgentsErbB ReceptorsFlavonesProto-Oncogene Proteins c-aktSTAT3 Transcription FactoracacetinAKTcancerEGFRmolecular dockingnetwork pharmacologySTAT3

Identifiers

PMID41096701
PMCPMC12524879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.